The experimental and clinical studies relevant to atherosclerosis and dyslipidemia were followed by the work of Okamoto et al. [31] who assessed the anti-inflammatory effects of PPARα activation in rheumatoid synovial fibroblasts (RSF) cultures and in a rodent model of inflammatory arthritis. Here, PPARA is linked to metabolic syndrome.